Aberrant PSA glycosylation—a sweet predictor of prostate cancer
Top Cited Papers
- 15 January 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Urology
- Vol. 10 (2), 99-107
- https://doi.org/10.1038/nrurol.2012.258
Abstract
Prostate cancer—the most commonly diagnosed cancer in men worldwide—can have a substantial effect on quality of life, regardless of the route the cancer takes. The serum PSA assay is the current gold standard option for diagnosing prostate cancer. However, a growing body of evidence suggests that PSA screening for prostate cancer results in extensive overdiagnosis and overtreatment. It is increasingly evident that the potential harm from overdiagnosis (in terms of unnecessary biopsies) must be weighed against the benefit derived from the early detection and treatment of potentially fatal prostate cancers. Rapid screening methods have been used to analyse glycosylation patterns on glycoproteins in large cohorts of patients, enabling the identification of a new generation of disease biomarkers. Changes to the expression status of certain glycan structures are now widely thought to be common features of tumour progression. In light of this development, much research has focused on the potential role of altered PSA glycosylation patterns in discriminating between significant and insignificant prostate cancers, with the aim of developing a more reliable diagnostic tool than the current serum PSA test.Keywords
This publication has 99 references indexed in Scilit:
- Screening for Prostate Cancer: Early Detection or Overdetection?Annual Review of Medicine, 2012
- Sialylation and fucosylation of epidermal growth factor receptor suppress its dimerization and activation in lung cancer cellsProceedings of the National Academy of Sciences of the United States of America, 2011
- A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen RangeJournal of Urology, 2011
- Beyond natural antibodies: the power of in vitro display technologiesNature Biotechnology, 2011
- EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised DiseaseEuropean Urology, 2011
- Estimates of cancer incidence and mortality in Europe in 2008European Journal of Cancer, 2010
- Nanoparticle-based bio-barcode assay redefines “undetectable” PSA and biochemical recurrence after radical prostatectomyProceedings of the National Academy of Sciences of the United States of America, 2009
- Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancerCurrent Opinion in Urology, 2009
- Glycoproteomics for Prostate Cancer Detection: Changes in Serum PSA Glycosylation PatternsJournal of Proteome Research, 2008
- Alterations in the Serum Glycome Due to Metastatic Prostate CancerJournal of Proteome Research, 2007